Distinguished New Board Member at American Skin Association
The American Skin Association (ASA) is thrilled to announce the addition of Dr. Steven A. Rosenberg, MD, PhD, as a new member of its esteemed Board of Directors. Dr. Rosenberg is recognized globally for his pioneering work in cancer immunotherapy. His extensive experience will enhance ASA's mission to promote research, education, and advocacy in skin health.
Transformative Leadership in Cancer Treatment
As Chief of the Surgery Branch at the National Cancer Institute (NCI), Dr. Rosenberg has spearheaded groundbreaking initiatives that have significantly changed the landscape for patients facing advanced cancers. His contributions are crucial in the realm of immune-based therapies, and he holds an h-index of 222, showcasing the considerable influence of his research within the scientific community.
Dr. Rosenberg has published more than 1,200 scientific articles, reinforcing his reputation as one of the leading figures in biomedical research. His innovative work focuses on cell transfer immunotherapy, which has resulted in durable complete remissions for patients suffering from metastatic melanoma and other aggressive solid tumors. Additionally, his laboratory was at the forefront of the first human gene transfer experiments, marking a pivotal advance in gene therapy.
Acknowledgment of Contributions
Howard P. Milstein, Chairman of ASA, expressed enthusiasm about Dr. Rosenberg's appointment, stating, "I am delighted to welcome Dr. Rosenberg to our Board. His dedication to advancing scientific discovery and his remarkable contributions to medicine will bolster our efforts in combating skin diseases and enhancing patient outcomes." This sentiment is echoed throughout the organization, with ASA’s President, James Krueger, MD, emphasizing Dr. Rosenberg's invaluable clinical expertise.
Innovations in Immunotherapy
In recent projects, Dr. Rosenberg’s team has made strides in developing adoptive cell therapies, particularly through genetically engineered lymphocytes. Techniques like CAR-mediated and TCR-directed therapies provide substantial clinical benefits, especially for individuals battling melanoma, lymphomas, and sarcomas. His current research endeavors aim to elucidate how the immune system detects and fights cancer, which holds promise for enhancing future immunotherapy options.
Educational Background and Professional Roles
Dr. Rosenberg received his BA and MD from Johns Hopkins University and later earned a PhD in Biophysics from Harvard University, where he explored the proteins of erythrocyte membranes in his dissertation. In addition to his role at NCI, he is a Professor of Surgery at the Uniformed Services University of Health Sciences and George Washington University School of Medicine and Health Sciences. Furthermore, he serves as a Foreign Adjunct Professor in Cell Therapy at the Karolinska Institutet in Sweden.
ASA takes pride in the expertise Dr. Rosenberg brings to the Board of Directors. His skills and insights will greatly benefit the organization's ongoing commitment to improving skin health through targeted research and education.
About American Skin Association
The American Skin Association is a collaborative effort involving patients, families, advocates, physicians, and scientists that has flourished for nearly four decades. The organization plays an integral role in combatting melanoma, vitiligo, psoriasis, atopic dermatitis, and other skin disorders that affect over 100 million individuals in the United States. ASA focuses on promoting research, championing skin health, especially among children, and enhancing public awareness about skin diseases. As a 501(c)(3) nonprofit organization, ASA is dedicated to advancing its mission.
American Skin Association proudly holds Candid's Seal of Platinum Transparency for the year 2026 and has received a Four-Star Rating from Charity Navigator.
Frequently Asked Questions
Who is Steven A. Rosenberg?
Dr. Steven A. Rosenberg is a leading expert in cancer immunotherapy and the newest member of the American Skin Association's Board of Directors.
What is the role of the American Skin Association?
The ASA aims to advance research, support education, and advocate for improved skin health, particularly for those affected by various skin disorders.
How has Dr. Rosenberg contributed to cancer care?
Dr. Rosenberg has developed innovative immune-based therapies that have transformed treatment options for patients with advanced malignancies.
What educational background does Dr. Rosenberg have?
He earned a BA and MD from Johns Hopkins University and a PhD in Biophysics from Harvard University, specializing in erythrocyte membrane proteins.
Why is Dr. Rosenberg's appointment important for ASA?
His expertise in immunotherapy and cancer research is expected to strengthen ASA's mission to combat skin disease and enhance patient outcomes through scientific innovation.
